Utah medical marijuana sales up nearly 60% to $118.7 million in 2022
Medical cannabis sales in Utah increased by 59% between 2021 and 2022, according to data published by the Utah Department of Health & Human Services’ Center for Medical Cannabis.
Medical cannabis sales in Utah increased by 59% between 2021 and 2022, according to data published by the Utah Department of Health & Human Services’ Center for Medical Cannabis.
With the start of a new year, cannabis companies across the country are tweaking their business models to meet changing laws and regulations that could affect sales and how they run their operations.
Utah regulators say they’re pushing for new rules governing the presence of delta-8 THC and other synthetic cannabinoids allowed in the state’s medical marijuana supply.
The parent company of the High Times marijuana brand signed a definitive agreement to acquire the California operations of multistate company Moxie.
U.S. cannabis sales through July were a mixed bag across the country, as consumers adjusted to historic inflation and shrinking disposable income, according to an analysis of state sales data by MJBizDaily.
Utah banned smokable hemp and CBD in food under a new law that also shifts oversight of the plant’s production to the U.S. Department of Agriculture.
A measure signed into law in March to increase access to Utah’s medical marijuana program still hasn’t been implemented, frustrating patient advocates and costing operators potential business.